Cardiovascular and Hematological Disorders - Drug Targets : Impact Factor & More
eISSN: 2212-4063pISSN: 1871-529X
Share this on:
Key Metrics
CiteScore 
2.6
SNIP
0.4
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Cardiovascular and Hematological Disorders - Drug Targets Journal Specifications
| Overview | |
| Publisher | BENTHAM SCIENCE PUBL LTD |
| Frequency | Semi-annual |
| General Details |
View less
Planning to publish in Cardiovascular and Hematological Disorders - Drug Targets ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cardiovascular and Hematological Disorders - Drug Targets
Effective Lowering of Lipoprotein (a) - A New Frontier in Cardiovascular Risk Reduction.
- 30 Jun 2026
- Cardiovascular & hematological disorders drug targets
Innovations in Hemorrhage Management: Calcium Alginate, Celox, and Desmopressin as Next-generation Hemostatic Agents.
- 12 Jun 2026
- Cardiovascular & hematological disorders drug targets
Plant-Derived Therapeutics for Androgen Deficiency Syndrome.
- 21 May 2026
- Cardiovascular & hematological disorders drug targets
Zerlasiran for Lipoprotein(a) Reduction: Mechanisms, Evidence, and Future Directions.
- 12 May 2026
- Cardiovascular & hematological disorders drug targets
The Role of Retinoid X Receptor Signaling in Multi-organ Ischemia/Reperfusion Injury: A Comprehensive Review.
- 6 May 2026
- Cardiovascular & hematological disorders drug targets
Targeting Hyperlipidemia: Investigating the Regulatory Roles of NPC1L1 and SREBP-2 and the Therapeutic Potential of Bioactive Compounds.
- 6 May 2026
- Cardiovascular & hematological disorders drug targets
Effective Lowering of Lipoprotein (a) - A New Frontier in Cardiovascular Risk Reduction.
- 30 Jun 2026
- Cardiovascular & hematological disorders drug targets
Innovations in Hemorrhage Management: Calcium Alginate, Celox, and Desmopressin as Next-generation Hemostatic Agents.
- 12 Jun 2026
- Cardiovascular & hematological disorders drug targets
Plant-Derived Therapeutics for Androgen Deficiency Syndrome.
- 21 May 2026
- Cardiovascular & hematological disorders drug targets
Zerlasiran for Lipoprotein(a) Reduction: Mechanisms, Evidence, and Future Directions.
- 12 May 2026
- Cardiovascular & hematological disorders drug targets
The Role of Retinoid X Receptor Signaling in Multi-organ Ischemia/Reperfusion Injury: A Comprehensive Review.
- 6 May 2026
- Cardiovascular & hematological disorders drug targets
Targeting Hyperlipidemia: Investigating the Regulatory Roles of NPC1L1 and SREBP-2 and the Therapeutic Potential of Bioactive Compounds.
- 6 May 2026
- Cardiovascular & hematological disorders drug targets
FAQs on Cardiovascular and Hematological Disorders - Drug Targets
What is the publishing frequency of Cardiovascular and Hematological Disorders - Drug Targets? 
How many articles did Cardiovascular and Hematological Disorders - Drug Targets publish last year?
What is the eISSN & pISSN for Cardiovascular and Hematological Disorders - Drug Targets?
What is Citescore for Cardiovascular and Hematological Disorders - Drug Targets?
What is SNIP score for Cardiovascular and Hematological Disorders - Drug Targets?
Who is the publisher of Cardiovascular and Hematological Disorders - Drug Targets?
